Information Provided By:
Fly News Breaks for May 18, 2017
LJPC
May 18, 2017 | 13:21 EDT
SunTrust analyst Yatin Suneja is "pleasantly surprised" by La Jolla Pharmaceutical's announcement today that the New England Journal of Medicine will publish LJPC-501's Phase III study in catecholamine-resistant hypotension. The "highly prestigious" journal publication highlights both the high unmet need in the CRH population and the benefit LJPC-501 could provide, Suneja tells investors in a research note. He has a Buy rating on the shares with a $57 price target. La Jolla in afternoon trading is up 15%, or $4.32, to $32.34.
News For LJPC From the Last 2 Days
There are no results for your query LJPC